Loading
companiesCompany
Abbisko Therapeutics
Abbisko is a Shanghai biotech listed in Hong Kong whose CSF-1R inhibitor pimicotinib met its phase 3 endpoint in tenosynovial giant cell tumour, a rare joint tumour, and is licensed to Merck KGaA.
Also called: Abbisko Therapeutics Co, Ltd和誉生物
Overview
Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour and is partnered with Merck KGaA outside China; FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.
Headquarters
Shanghai, CN
Scorecard
All companies#309of 1244 companies, score 13
- phase 1/2 +2
- targets +4
- modalities +2
- registry trials +5
0 approved, 0 in phase 3, 2 earlier, 2 targets, 7 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2small molecule (structure undisclosed or not yet in PubChem)
ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.
Phase 2Oral kinase inhibitor
Pimicotinib is an oral kinase inhibitor from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, in registered phase 2 trials for tenosynovial giant cell tumour.
Similar pages
- TrialStudy of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Shares Pimicotinib, Tenosynovial giant cell tumour (TGCT), Merck KGaA (EMD Serono).
- TargetFGF19
Shares ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression, Hepatocellular carcinoma.
- CompanyThreshold Pharmaceuticals
Shares Merck KGaA (EMD Serono), Pivotal (registrational) trial, Clinical trial.
- CompanyImmunitor
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- Key paperPexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- TrialENLIVEN
- CompanyCan-Fite BioPharma
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
cancers
targets
drugs
Phase 2small molecule (structure undisclosed or not yet in PubChem)
Phase 2Oral kinase inhibitor
companies
terms
trials
A Phase 2 Clinical Study of ABSK061 and ABSK043A Phase 2 Clinical Study of Combination Therapy With ABSK043 and FirmonertinibA Phase 2 Clinical Study of Combination Therapy With ABSK043 and GlecirasibA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic CancerA Phase 2 Study of ABSK043 Combined With OsimertinibA Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)